Cerity Partners LLC Lowers Holdings in Danaher Corporation $DHR

Cerity Partners LLC decreased its position in shares of Danaher Corporation (NYSE:DHR) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 332,416 shares of the conglomerate’s stock after selling 10,460 shares during the quarter. Cerity Partners LLC’s holdings in Danaher were worth $65,905,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in DHR. Ceredex Value Advisors LLC lifted its stake in shares of Danaher by 1.6% during the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares during the last quarter. Chicago Capital LLC raised its holdings in Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after purchasing an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. lifted its position in shares of Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after buying an additional 30,300 shares during the last quarter. Nvwm LLC boosted its holdings in shares of Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after buying an additional 1,204 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. grew its position in shares of Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after buying an additional 6,136 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 over the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DHR shares. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 target price (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Evercore ISI reaffirmed an “outperform” rating and set a $250.00 price target on shares of Danaher in a research report on Monday. Morgan Stanley began coverage on Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Finally, Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.92.

Danaher Stock Down 0.4%

Shares of DHR stock opened at $235.60 on Thursday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The firm has a market capitalization of $166.41 billion, a PE ratio of 48.58, a P/E/G ratio of 4.21 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock’s 50-day simple moving average is $224.91 and its 200-day simple moving average is $210.05.

Danaher (NYSE:DHR) last issued its earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the firm earned $1.71 earnings per share. Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.5%. Danaher’s dividend payout ratio is presently 26.39%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.